A group of peptides could be a step closer to becoming available through certain pharmacies after key Food and Drug Administration (FDA) committee votes last week.
On Thursday and Friday, the FDA's Pharmacy Compounding Advisory Committee (PCAC) voted to recommend adding six peptides to the 503A bulks list for specific uses. The newly PCAC-recommended peptides include BPC-157, KPV, TB-500, MOTS-c, Epitalon, and Semax. If the FDA approves adding these peptides to the list, compounding pharmacies could use them to make customized medications for patients. The committee voted against recommending emideltide for opioid withdrawal, chronic insomnia, and narcolepsy uses.
